Bioventus, Inc.

As of May 10, 2022, Bioventus, Inc. is considered a risky investment due to its high valuation metrics and significant underperformance compared to the S&P 500, indicating it may be overvalued.

As of May 10, 2022, Bioventus, Inc. is considered overvalued and risky due to its high P/E ratio of 345, poor return metrics, and significant year-to-date decline of 37.9%, contrasting with the S&P 500's gain.

As of April 28, 2025, Bioventus, Inc. is in a bearish trend with strong indications of weakness, supported by bearish MACD, moving averages, and Bollinger Bands, suggesting potential for further downside.

Bioventus, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $124 million and a net profit of -$3 million. It has a market cap of $521.62 million and key metrics including a P/E ratio of 345.00 and a debt-to-equity ratio of 2.20.

As of Jun 18, Bioventus, Inc. has a market capitalization of 521.62 million and reported net sales of 567.70 million with a net profit of -41.17 million for the latest four quarters. Shareholder's funds are 147.94 million, and total assets amount to 727.96 million.